JosÃ© Luis Molinuevo

List of Publications by Year
in descending order

276 papers	28,691 citations	13099 68 h-index	6131 159 g-index
289 all docs	289 docs citations	289 times ranked	23884 citing authors

#	Article	IF	Citations
1	Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
2	Genotypic effects of <i>APOE</i>-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. Cerebral Cortex, 2023, 33, 2748-2760.	2.9	5
3	Soundtrack of life: An fMRI study. Behavioural Brain Research, 2022, 418, 113634.	2.2	0
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
5	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	2.6	5
6	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
7	Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts. Molecular Psychiatry, 2022, 27, 2010-2018.	7.9	9
8	The protective gene dose effect of the <i>APOE</i><i>ε2</i> allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.8	13
9	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
10	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
11	Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	3.3	12
12	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
13	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579.	6.4	16
14	Nonlinear interaction between <scp>APOE</scp><i>ε</i>4 allele load and age in the hippocampal surface of cognitively intact individuals. Human Brain Mapping, 2021, 42, 47-64.	3.6	12
15	Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12205.	2.4	7
16	Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12155.	3.7	13
17	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychotherapy and Psychosomatics, 2021, 90, 341-350.	8.8	18
18	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology, 2021, 77, 888-898.	2.8	24

#	Article	IF	Citations
19	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2169-2182.	6.4	24
20	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 1015-1021.	2.6	8
21	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 46.	6.2	9
22	Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's<i>continuum</i>. Alzheimer's and Dementia, 2021, 17, 788-800.	0.8	14
23	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.8	51
24	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	6.4	16
25	Management and Quality Control of Large Neuroimaging Datasets: Developments From the Barcelonaβeta Brain Research Center. Frontiers in Neuroscience, 2021, 15, 633438.	2.8	9
26	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
27	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity. International Journal of Geriatric Psychiatry, 2021, 36, 1037-1049.	2.7	6
28	Genetic Influences on Hippocampal Subfields. Neurology: Genetics, 2021, 7, e591.	1.9	8
29	Genetic Predisposition to Alzheimer's Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. Genes, 2021, 12, 825.	2.4	7
30	Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134.	6.2	8
31	Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	3.1	13
32	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
33	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. Alzheimer's Research and Therapy, 2021, 13, 135.	6.2	30
34	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 697234.	3.4	17
35	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2021, 84, 119-128.	2.6	3
36	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. Neurology, 2021, 97, e2065-e2078.	1.1	40

#	Article	IF	Citations
37	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environment International, 2021, 157, 106864.	10.0	40
38	Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 740005.	3.4	4
39	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
40	Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	6.2	15
41	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
42	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	9.0	204
43	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
44	Self-reflection is associated with markers of Alzheimer's disease in cognitively unimpaired older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	1
45	Network analysis for studying the dynamics of affective symptoms and treatment adherence in APOEɛ4 carriers with subjective cognitive decline following a multimodal intervention: Preliminary findings from the PENSA Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
46	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging and Behavior, 2020, 14, 2012-2023.	2.1	40
47	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
48	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. Alzheimer's Research and Therapy, 2020, 12, 4.	6.2	53
49	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
50	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
51	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
52	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. Journal of Alzheimer's Disease, 2020, 76, 1413-1422.	2.6	4
53	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12021.	2.4	15
54	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology, 2020, 95, e2065-e2074.	1.1	3

#	Article	IF	Citations
55	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study. Brain Structure and Function, 2020, 225, 2331-2345.	2.3	5
56	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in Aβ pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
57	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.8	0
58	Use of the Medtep digital health platform in the framework of a multimodal intervention in patients with subjective cognitive decline (PENSA Study). Alzheimer's and Dementia, 2020, 16, e040447.	0.8	0
59	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. Alzheimer's and Dementia, 2020, 16, e042653.	0.8	0
60	Polygenic-wide analysis to assess the impact of genetic risk profiles on brain morphometry in the ALFA study. Alzheimer's and Dementia, 2020, 16, e042952.	0.8	0
61	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e042955.	0.8	0
62	Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. Alzheimer's and Dementia, 2020, 16, e043520.	0.8	0
63	Amyloid-β, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044444.	0.8	0
64	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466.	0.8	1
65	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720.	0.8	0
66	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722.	0.8	0
67	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044733.	0.8	0
68	Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. Alzheimer's and Dementia, 2020, 16, e044780.	0.8	0
69	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808.	0.8	0
70	PENSA study: Study design, recruitment profiles and participant inclusion in multimodal intervention studies. Alzheimer's and Dementia, 2020, 16, e045074.	0.8	0
71	APOE ·ε4 shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092.	0.8	0
72	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. Alzheimer's and Dementia, 2020, 16, e045137.	0.8	0

#	Article	IF	Citations
73	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171.	0.8	0
74	Between‐country harmonization and differences of the Lifetime of Experiences Questionnaire (LEQ) for lifespan complex mental activity assessment. Alzheimer's and Dementia, 2020, 16, e045240.	0.8	1
75	Incidence of subjective cognitive decline is associated with amyloid‐β pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293.	0.8	0
76	Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. Alzheimer's and Dementia, 2020, 16, e045294.	0.8	2
77	Amyloid‐positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715.	0.8	0
78	The Barcelonabeta dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies â€" An update. Alzheimer's and Dementia, 2020, 16, e045800.	0.8	0
79	Impact of APOE ε4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e045828.	0.8	1
80	ALFA+: A cohort study to understand and model the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045935.	0.8	0
81	Quantitative informant‐and self‐reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12127.	2.4	6
82	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>. Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.8	120
83	APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. Cerebral Cortex, 2020, 30, 4110-4120.	2.9	7
84	NeAT: a Nonlinear Analysis Toolbox for Neuroimaging. Neuroinformatics, 2020, 18, 517-530.	2.8	0
85	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer's dementia. Environment International, 2020, 138, 105546.	10.0	69
86	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. Neurobiology of Aging, 2020, 95, 104-114.	3.1	15
87	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	10.2	627
88	Dementia care during COVID-19. Lancet, The, 2020, 395, 1190-1191.	13.7	412
89	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
90	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. Frontiers in Aging Neuroscience, 2020, 12, 622360.	3.4	9

#	Article	IF	Citations
91	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
92	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18 F]flutemetamol PET images. Alzheimer's and Dementia, 2020, 16, .	0.8	0
93	A co‐creation approach to design the implementation of a multimodal intervention in patients with subjective cognitive decline (PENSA study). Alzheimer's and Dementia, 2020, 16, e042998.	0.8	0
94	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	2.6	18
95	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer's Research and Therapy, 2019, 11, 72.	6.2	23
96	The *MS4A* gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
97	Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels. Journal of Alzheimer's Disease, 2019, 72, 1287-1302.	2.6	6
98	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	6.2	28
99	Interactive effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middle-aged subjects. NeuroImage: Clinical, 2019, 24, 101983.	2.7	30
100	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. Alzheimer's Research and Therapy, 2019, 11, 12.	6.2	46
101	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	6.2	23
102	Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease, 2019, 70, 323-341.	2.6	146
103	Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 164-174.	3.7	30
104	APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. NeuroImage: Clinical, 2019, 23, 101818.	2.7	18
105	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
106	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	6.2	82
107	Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1299-1308.	6.4	10
108	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101777.	2.7	29

#	Article	IF	Citations
109	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
110	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. NeuroImage: Clinical, 2019, 23, 101801.	2.7	26
111	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8
112	IC–02–05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERS. Alzheimer's and Dementia, 2019, 15, P4.	0.8	0
113	Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome. European Review of Aging and Physical Activity, 2019, 16, 23.	2.9	13
114	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	3.5	46
115	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
116	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.8	232
117	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
118	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 67, 303-313.	2.6	8
119	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
120	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.8	28
121	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. NeuroImage: Clinical, 2018, 19, 190-201.	2.7	16
122	Wishes and preferences for an online lifestyle program for brain health—A mixed methods study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 141-149.	3.7	11
123	NIA–AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
124	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077.	2.6	19
125	Long-term exposure to residential green and blue spaces and anxiety and depression in adults: A cross-sectional study. Environmental Research, 2018, 162, 231-239.	7.5	208
126	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	2.6	25

#	Article	IF	Citations
127	Learning non-linear patch embeddings with neural networks for label fusion. Medical Image Analysis, 2018, 44, 143-155.	11.6	21
128	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2018, 319, 130.	7.4	121
129	Tauopathy with Hippocampal 4‐Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. Brain Pathology, 2018, 28, 284-286.	4.1	4
130	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
131	Effects of <i>APOE</i>‐ε4 allele load on brain morphology in a cohort of middle‐aged healthy individuals with enriched genetic risk for Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 902-912.	0.8	98
132	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
133	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
134	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
135	P2‐262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
136	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimer's Research and Therapy, 2018, 10, 123.	6.2	73
137	The SCD‐Well randomized controlled trial: Effects of a mindfulness‐based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	3.7	26
138	Computer‐assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.4	8
139	European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open, 2018, 8, e021017.	1.9	72
140	Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
141	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. Alzheimer's Research and Therapy, 2018, 10, 116.	6.2	28
142	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
143	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.8	163
144	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46

#	Article	IF	Citations
145	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.8	0
146	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. Human Brain Mapping, 2018, 39, 4565-4579.	3.6	32
147	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.8	87
148	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191.	2.6	15
149	MRI-Based Screening of Preclinical Alzheimerâ€™s Disease for Prevention Clinical Trials. Journal of Alzheimer's Disease, 2018, 64, 1099-1112.	2.6	18
150	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
151	White matter microstructure is altered in cognitively normal middle-aged APOE-Îµ4 homozygotes. Alzheimer's Research and Therapy, 2018, 10, 48.	6.2	43
152	Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. Methods in Molecular Biology, 2018, 1750, 165-184.	0.9	0
153	The <i>APOE</i> Îµ4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	2.4	36
154	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
155	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
156	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
157	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
158	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. BMJ Open, 2017, 7, e013215.	1.9	28
159	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
160	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108
161	Alzheimerâ€™s disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71.	6.2	424
162	Cost-Utility of Using Alzheimerâ€™s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 1477-1487.	2.6	31

#	Article	IF	Citations
163	Frontotemporal Dementia Caused by the P301L Mutation in the<i> MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
164	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. NeuroImage: Clinical, 2017, 16, 343-354.	2.7	73
165	Effect of long-term exposure to air pollution on anxiety and depression in adults: A cross-sectional study. International Journal of Hygiene and Environmental Health, 2017, 220, 1074-1080.	4.3	161
166	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
167	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	4.0	119
168	[P2â€"355]: CSF STREM2, BUT NOT YKLâ€40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P758.	0.8	0
169	[P1â€"058]: RESPONDER ANALYSIS OF THE COGNITIVE EFFECT OF COMBINATION THERAPY WITH DONEPEZIL AND INTEPIRDINE (RVTâ€101) VERSUS DONEPEZIL MONOTHERAPY: RESULTS FROM A 48â€WEEK MULTINATIONAL PLACEBOâ€CONTROLLED STUDY IN MILD TO MODERATE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P259.	0.8	2
170	[P3â€"566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1195.	0.8	0
171	[P4â€"157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.8	4
172	[P4â€"214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. Alzheimer's and Dementia, 2017, 13, P1348.	0.8	0
173	[P4â€"377]: EXPECTATIONS RELATED TO THE IMPLICATIONS OF LEARNING ALZHEIMER's DISEASE RISK AMONG COGNITIVELY HEALTHY RESEARCH PARTICIPANTS. Alzheimer's and Dementia, 2017, 13, P1437.	0.8	0
174	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.8	0
175	[P1â€"289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.8	0
176	[P2â€"212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.8	1
177	[O1â€"11â€"03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.8	0
178	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. Journal of Alzheimer's Disease, 2017, 61, 689-703.	2.6	33
179	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	3.1	34
180	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	2.6	23

#	Article	IF	Citations
181	Cerebrospinal Fluid AÎ²42/40 Corresponds Better than AÎ²42 to Amyloid PET in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	2.6	191
182	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	2.6	17
183	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	2.6	17
184	P2-302: CSF Beta-Amyloid- and APOE Æ4-Related Decline in Episodic Memory Over 12 Months Measured using the Cantab in Individuals with Amnestic MCI: Results from the European ADNI Study. , 2016, 12, P751-P751.		2
185	P3â€315: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.8	1
186	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	3.7	97
187	Modeling practice effects in healthy middleâ€aged participants of the Alzheimer and Families parent cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 149-158.	2.4	6
188	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	2.6	18
189	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	3.1	5
190	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.8	86
191	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.8	0
192	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neurodegenerative Diseases, 2016, 16, 69-76.	1.4	36
193	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	3.1	54
194	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry,the, 2016, 3, 179-186.	7.4	171
195	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	4.0	15
196	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
197	Informantsâ€™ Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimerâ€™s Disease from NormalÂAging. Journal of Alzheimer's Disease, 2015, 48, S87-S98.	2.6	50
198	Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimerâ€™s dementia: a pooled area under the curve analysis. Alzheimer's Research and Therapy, 2015, 7, 28.	6.2	57

#	Article	IF	Citations
199	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
200	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	3.1	30
201	Correlates of cerebrospinal fluid levels of oligomeric- and total-Î±-synuclein in premotor, motor and dementia stages of Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 294-306.	3.6	85
202	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
203	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.2	3
204	Recomendaciones para la utilizaciÃ³n de biomarcadores de imagen PET en el proceso diagnÃ³stico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.0	16
205	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
206	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 455-461.	0.8	9
207	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 919-927.	2.6	32
208	Measuring decline in prodromal AD: a pike to hike. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 358-358.	1.9	1
209	Spanish Multicenter Normative Studies (NEURONORMA Project): Normative Data and Equivalence of Four BNT Short-Form Versions. Archives of Clinical Neuropsychology, 2014, 29, 60-74.	0.5	13
210	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 74.	9.0	59
211	Reply. Annals of Neurology, 2014, 75, 460-461.	5.3	0
212	Identification of blood serum microâ€RNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
213	Neuropathology of prodromal Lewy body disease. Movement Disorders, 2014, 29, 410-415.	3.9	71
214	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
215	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
216	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	1.9	55

#	Article	IF	Citations
217	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 901-908.	2.6	102
218	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.8	163
219	Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 777-788.	2.6	32
220	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. Neurobiology of Aging, 2014, 35, 2671-2680.	3.1	72
221	Five‐year follow‐up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Movement Disorders, 2014, 29, 1774-1780.	3.9	74
222	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	2.5	407
223	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 2013, 74, 655-668.	5.3	171
224	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
225	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1772-1778.	3.1	87
226	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurology, The, 2013, 12, 443-453.	10.2	602
227	Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer's Disease. Journal of Clinical Psychopharmacology, 2013, 33, 199-205.	1.4	40
228	Clinical Observational Research on Alzheimer's Disease: What Clinical Trial Registries Can Tell. Journal of Alzheimer's Disease, 2013, 34, 183-190.	2.6	2
229	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. Journal of Alzheimer's Disease, 2013, 36, 165-175.	2.6	19
230	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. Neurodegenerative Diseases, 2012, 10, 158-160.	1.4	12
231	The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Molecular Medicine Reports, 2012, 5, 1111-1115.	2.4	17
232	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.8	271
233	Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 31-37.	2.8	32
234	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. Journal of Alzheimer's Disease, 2012, 31, 581-591.	2.6	31

#	Article	IF	Citations
235	Using artificial neural networks in clinical neuropsychology: High performance in mild cognitive impairment and Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 195-208.	1.3	39
236	Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiology of Aging, 2012, 33, 61-74.	3.1	241
237	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. International Journal of Geriatric Psychiatry, 2012, 27, 127-134.	2.7	38
238	APOE Status Modulates the Changes in Network Connectivity Induced by Brain Stimulation in Non-Demented Elders. PLoS ONE, 2012, 7, e51833.	2.5	34
239	Specific Anatomic Associations Between White Matter Integrity and Cognitive Reserve in Normal and Cognitively Impaired Elders. American Journal of Geriatric Psychiatry, 2011, 19, 33-42.	1.2	36
240	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neuroscience Letters, 2011, 496, 40-42.	2.1	13
241	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. Journal of Hepatology, 2011, 55, 564-573.	3.7	96
242	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
243	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. Journal of Alzheimer's Disease, 2011, 23, 319-326.	2.6	66
244	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Research - Neuroimaging, 2011, 192, 140-146.	1.8	19
245	Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2011, 10, 797-805.	10.2	293
246	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. Journal of Neural Transmission, 2011, 118, 259-262.	2.8	49
247	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with <i>PSEN1</i> Mutations. Neurodegenerative Diseases, 2011, 8, 202-207.	1.4	24
248	Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test. Archives of Clinical Neuropsychology, 2011, 26, 144-157.	0.5	36
249	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 53-59.	1.7	52
250	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	2.6	136
251	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2010, 9, 1070-1077.	10.2	349
252	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnestic mild cognitive impairment and mild Alzheimer's disease. Cortex, 2010, 46, 451-461.	2.4	136

#	Article	IF	Citations
253	Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder. Sleep Medicine, 2010, 11, 534-539.	1.6	97
254	Spanish Multicenter Normative Studies (NEURONORMA Project): Methods and Sample Characteristics. Archives of Clinical Neuropsychology, 2009, 24, 307-319.	0.5	206
255	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Visual Object and Space Perception Battery-Abbreviated, and Judgment of Line Orientation. Archives of Clinical Neuropsychology, 2009, 24, 355-370.	0.5	32
256	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Fluency Tests. Archives of Clinical Neuropsychology, 2009, 24, 395-411.	0.5	201
257	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. Biological Psychology, 2009, 80, 256-259.	2.2	81
258	Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1114-1124.	3.1	315
259	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Stroop Color-Word Interference Test and the Tower of London-Drexel. Archives of Clinical Neuropsychology, 2009, 24, 413-429.	0.5	75
260	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Span, Visuospatial Span, Letter and Number Sequencing, Trail Making Test, and Symbol Digit Modalities Test. Archives of Clinical Neuropsychology, 2009, 24, 321-341.	0.5	149
261	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth Complex Figure (Copy and Memory), and Free and Cued Selective Reminding Test. Archives of Clinical Neuropsychology, 2009, 24, 371-393.	0.5	133
262	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Boston Naming Test and Token Test. Archives of Clinical Neuropsychology, 2009, 24, 343-354.	0.5	74
263	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. Journal of Neurology, 2008, 255, 488-494.	3.6	40
264	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2008, 270, 94-98.	0.6	35
265	Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 1-6.	1.3	45
266	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 845-846.	1.9	11
267	Clinical and Pathological Heterogeneity of Neuronal Intermediate Filament Inclusion Disease. Archives of Neurology, 2008, 65, 272-5.	4.5	27
268	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurology, The, 2006, 5, 572-577.	10.2	901
269	Repetitive Transcranial Magnetic Stimulation Effects on Brain Function and Cognition among Elders with Memory Dysfunction. A Randomized Sham-Controlled Study. Cerebral Cortex, 2006, 16, 1487-1493.	2.9	169
270	A Novel Mutation in the PSEN2 Gene (T430M) Associated With Variable Expression in a Family With Early-Onset Alzheimer Disease. Archives of Neurology, 2003, 60, 1149.	4.5	46

#	Article	IF	Citations
271	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Movement Disorders, 2002, 17, 372-377.	3.9	148
272	Further extension of the H1 haplotype associated with progressive supranuclear palsy. Movement Disorders, 2002, 17, 550-556.	3.9	61
273	Prepulse modulation of the startle reaction and the blink reflex in normal human subjects. Experimental Brain Research, 1999, 129, 49-56.	1.5	79
274	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. Neuroscience Letters, 1999, 275, 183-186.	2.1	56
275	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Annals of Neurology, 1998, 44, 976-980.	5.3	140
276	Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection. Archives of Neurology, 1998, 55, 1122.	4.5	85